Arcutis Biotherapeutics Q2 2024 GAAP EPS $(0.42) Beats $(0.51) Estimate, Sales $30.86M Beat $27.73M Estimate
Author: Benzinga Newsdesk | August 14, 2024 04:01pm
Arcutis Biotherapeutics (NASDAQ:
ARQT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.51) by 17.65 percent. This is a 63.79 percent increase over losses of $(1.16) per share from the same period last year. The company reported quarterly sales of $30.86 million which beat the analyst consensus estimate of $27.73 million by 11.27 percent. This is a 494.57 percent increase over sales of $5.19 million the same period last year.
Posted In: ARQT